Skip to main content
. Author manuscript; available in PMC: 2025 Dec 24.
Published in final edited form as: Sleep Med. 2025 Oct 14;136:106853. doi: 10.1016/j.sleep.2025.106853

Fig. 4.

Fig. 4.

Linear regression analysis. Linear regression analysis demonstrating associations (A) between percent change in weight and percent change in AHI; (B) between percent change in weight and percent change in SASHB; and (C) between percent change in AHI and percent change in SASHB. For each response variable, 3 models were fit, 1 only on the participants treated with TZP, 1 only on the participants treated with placebo, and 1 on the data combined across the two treatment arms. AHI = apnea-hypopnea index; SASHB = sleep apnea-specific hypoxic burden; TZP = tirzepatide maximum tolerated dose (MTD, 10 mg or 15 mg once weekly).